SCHEMBL18980949

SCHEMBL18980949

Cc1ccc(S(=O)(=O)NCc2ccccc2-c2ccc(Cl)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.62
MEN1 O00255 2/20 0.62
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
ATM Q13315 2/20 0.54
CA12 O43570 2/20 0.54
CA9 Q16790 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
LMNA P02545 4/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 2/20 0.49
TP53 P04637 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ALDH1A1 P00352 1/20 0.49
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18980588 0.87 KMT2A (0.62) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL18980898 0.85 ALDH1A1 (0.64) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL5960083 0.80 KMT2A (0.72) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL15712142 0.78 MEN1 (0.53) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL5960116 0.77 MEN1 (0.73) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL12406975 0.77 KMT2A (1.00) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL29095262 0.76 ALDH1A1 (0.55) KMT2AMEN1CYP1A2CYP3A4ATM
Hydrochloric Acid SCHEMBL17160811 0.76 MEN1 (0.51) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL12530337 0.75 MEN1 (0.64) KMT2AMEN1CYP1A2CYP3A4ATM
SCHEMBL12406976 0.75 KMT2A (0.64) KMT2AMEN1CYP1A2CYP3A4ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10118169-B2 Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis THE UNIVERSITY OF CHICAGO (US) 2018-11-06 US disclosed
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170173572-A1 CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS POF1B, FGFR1, COASY KMT2A 2292/4885MEN1 3486/4885CYP1A2 1613/4885
US-10118169-B2 Chiral ligand-based metal-organic frameworks for broad-scope asymmetric catalysis POF1B, FGFR1, COASY KMT2A 2292/4885MEN1 3486/4885CYP1A2 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.